依达拉奉联合溶栓治疗急性脑梗死效果研究

Analyze the Effect of Edaravone Combined With Thrombolysis in the Treatment of Acute Cerebral Infarction

目的:分析依达拉奉联合溶栓治疗急性脑梗死的临床疗效。方法:纳2019年3月—2020年10月进入我院治疗的急性脑梗死患者作课题研究主体,合计54例,对每位患者进行入院编码,将1~27号患者纳入对照组,给予注射用阿替普酶静脉溶栓治疗,将28~54号患者纳入观察组,给予依达拉奉+注射用阿替普酶静脉溶栓治疗,评估两组患者治疗前后的NHISS评分与Barthel指数,检测炎症因子水平,比较临床治疗效果。结果:经过比较对照组与观察组治疗前的NHISS评分(12.99±3.25)分、(13.01±3.27)分与Barthel指数(60.35±6.23)分、(60.40±6.25)分,并未发现统计差异(P>0.05),经过治疗,提示观察组患者NHISS评分与Barthel指数分别是(6.03±1.21)分、(84.78±5.17)分,较对照组数据(8.92±1.47)分、(74.32±4.90)分更优,差异有统计学意义(P<0.05);观察组患者Hs-CRP、IL-6、TNF-α三项炎症因子水平分别是(6.58±2.83)mg/L、(55.09±4.11)ng/L、(8.01±1.59)ng/L,与对照组(9.58±3.19)mg/L、(70.88±5.32)ng/L、(14.90±3.35)ng/L相比更低,差异存在统计学意义(P<0.05);观察组患者治疗总有效率高达92.59%,相比对照组70.37%更高,差异有统计学(P<0.05)。结论:对于急性脑梗死患者,临床给予依达拉奉联合溶栓治疗的有效性较高,可以有效改善机体炎症,加快脑部神经功能的恢复速度,提高患者日常生活能力。

Objective:To analyze the clinical efficacy of edaravone combined with thrombolysis in the treatment of acute cerebral infarction.Methods:54 patients with acute cerebral infarction who were admitted to our hospital from March 2019 to October 2020 were selected as the research subjects.Each patient was coded for admission.Patients No.1 to 27 were included in the control group and given intravenous thrombolytic therapy with alteplase for injection.Patients No.28 to 54 were included in the observation group and given intravenous thrombolytic therapy with edaravone and alteplase for injection Nhiss score and Barthel index before and after treatment were used to detect the level of inflammatory factors,and the clinical effect was compared.Results:Comparing the scores of NHISS(12.99±3.25),(13.01±3.27)and Barthel index(60.35±6.23),(60.40±6.25)between the control group and the observation group before treatment,there was no statistical difference(P>0.05).It is suggested that the NHISS score and Barthel index in the observation group are(6.03±1.21)and(84.78±5.17)respectively,which are better than those in the control group(8.92±1.47)and(74.32±4.90),with statistical significance(P<0.05).The levels of Hs-CRP,IL-6 and TNF-αin the observation group were(6.58±2.83)mg/L/l,(55.09±4.11)ng/L/l and(8.01±1.59)ng/L/l,respectively,which were higher than those in the control group(9.58±3.19)mg/L The total effective rate in the observation group was as high as 92.59%,which was higher than that in the control group(70.37%,P<0.05).Conclusion:for patients with acute cerebral infarction,edaravone combined with thrombolytic therapy is effective,which can effectively improve the body inflammation,accelerate the recovery of brain nerve function,and improve the ability of daily life of patients.